

December 13, 2018



Boston Therapeutics Announces Marketing of Sugardown® in Asia

LAWRENCE, Mass., Dec. 13, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics, Inc. (the "**Company**" or "**BTI**") (OTCQB: BTHE), an innovator in the design, development and commercialization of novel therapeutics as an adjunct therapy for diabetes, signed a co-marketing agreement with Jin Long Health, a wholly owned subsidiary of China Hiking Group to market Sugardown® chewable tablets in China through Jin Long's distribution channels including online and dedicated healthcare outlets.

China Hiking Group is a diversified business conglomerate headquartered in Qingdao City, PRC, and ranked 69th place of China Top 100 Private Service Enterprises (www.hiking.cn), and its subsidiary Jin Long Health is dedicated to the promotion of quality healthcare and food products for promotion of public health and well-being of the population.

CEO Carl W. Rausch commented, "This co-marketing effort signifies a convergence of complementary resources of the two companies for the proper launch of Sugardown® in China." Ongoing communication networking with Microcap Headlines (<http://microcapheadlines.com>) will continue to bring awareness on Boston Therapeutics' unique product pipeline to the public.

About Boston Therapeutics, Inc. www.bostonti.com

Boston Therapeutics, headquartered in Lawrence, MA (OTCQB: BTHE) is an innovator in design, development and commercialization of novel non-systemic compounds to treat diabetes and diabetes related complications. The company has proprietary compounds based on glucose chemistry, peptide chemistry and protein conjugates.

Forward Looking Statement

This press release includes forward-looking statements. These statements may be identified by words such as "feel," "believes," "expects," "estimates," "projects," "intends," "should," "is to be," or the negative of such terms, or other comparable terminology. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from the forward-looking statements contained herein. Factors that could cause actual results to differ materially include, but are not limited to: our limited operations and need to expand in the near future; risks associated with obtaining regulatory approval of our products; the ability to protect our intellectual property; the potential lack of market acceptance of our products; potential competition; our inability to retain key members of our management team; our inability to raise additional capital to fund our operations and business plan; our ability to continue as a going concern; our

liquidity and other risks and uncertainties and other factors discussed from time to time in our filings with the Securities and Exchange Commission ("SEC"), including our annual report on Form 10-K filed with the SEC. Boston Therapeutics expressly disclaims any obligation to publicly update any forward-looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law.

Contact: Boston Therapeutics, Inc.
Stephen A. Spanos, Finance
Phone: 603-935-9799
Email: stephen.spanos@bostonti.com
www.bostonti.com



Source: Boston Therapeutics, Inc.